Immunic, Inc. (IMUX) Stock Forecast
IMUX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 12 analysts
- Price target
- $43.09 average of analyst targets
- Upside to target
- +518.2% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.82
- 52-week range
- $5.10 – $16.90
IMUX analyst ratings
12 analystsNumber of analysts at each rating.
IMUX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
IMUX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.96 | −$2.58 | −$0.67 | −$1.30 | +26.0% | 11 |
| Current fiscal year (2026) | −$3.57 | −$5.72 | −$3.09 | −$6.20 | +42.4% | 11 |
| Next fiscal year (2027) | −$2.43 | −$4.68 | −$0.70 | −$3.57 | +32.0% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
IMUX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 10 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 10 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 10 |
IMUX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
IMUX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.19 | −$1.18 | −$0.96 | −$0.96 | −$0.96 | −19.4% | 7 up · 3 down |
| Current fiscal year (2026) | −$4.38 | −$4.40 | −$3.57 | −$3.57 | −$3.57 | −18.6% | 6 up · 3 down |
| Next fiscal year (2027) | −$3.55 | −$3.63 | −$2.43 | −$2.43 | −$2.43 | −31.6% | 6 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
IMUX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; IMUX beat in 5 of 12.
What analysts expect from IMUX
12 analysts cover Immunic; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $43.09, 518.2% above the latest close of $6.97. Analysts expect earnings of −$3.57 per share for 2026, +42.4% from a year earlier. For 2027 the average estimate is −$2.43 per share. Immunic beat the EPS estimate in 5 of the last 12 quarters.
Related: IMUX income statement, IMUX key metrics, IMUX chart. See the IMUX stock overview for the latest quote and news.
IMUX forecast FAQ
What is Immunic's price target?
The average analyst price target for Immunic is $43.09, 518.2% above the latest close of $6.97.
Is Immunic a buy, hold or sell?
Of 12 analysts covering Immunic, 12 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Immunic's EPS forecast?
Analysts forecast −$3.57 per share for 2026 (range −$5.72 to −$3.09); for 2027 the estimate is −$2.43.
When does Immunic report earnings?
Immunic is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens; the EPS estimate is $-0.82.
Does Immunic usually beat earnings estimates?
Immunic reported EPS at or above the analyst estimate in 5 of the last 12 quarters.